New views on the role of endothelin

Endocrine Regulations

Volumn 36, Issue 4, 2002, Pages 161-167

  Goraca, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular effects; Endothelin; Minireview

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN RECEPTOR ANTAGONIST; PD 1611721; TAK 44;

ARTERIAL PRESSURE; ARTERY DILATATION; ARTERY RESISTANCE; CARDIOVASCULAR DISEASE; DRUG EFFECT; DRUG MECHANISM; HYPOTENSION; NONHUMAN; REVIEW;

ANIMALS; BLOOD PRESSURE; BLOOD VESSELS; DISEASE; ENDOTHELINS; HEART; HUMANS;

EID: 0037961650     PISSN: 12100668     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. YANAGISAWA M, KURIHARA H, KIMURA S, TOMBE Y, KOBAYASHI M: Nature (London) 332, 411-415, 1988.
2. HICKEY KA, RUBANYI G, PAUL RJ, HIGHSMITH RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 248, C550-C556, 1985.
3. PARISSOS JT, VENETSANOU KF, MENTZIKOF DG, KALANTZI MV, GEORGOPOULOU MV, CHRISTOPOULOS N, KARAS SM: Plasma levels of soluble cellular adhesion molecules in patients with arterial hypertension. Correlations with plasma endothelin-1. Eur Intern Med 12, 350-356, 2001.
4. INOUE A, YANAGISAWA M, KIMURA S, KASUYA Y, MIYAUCHI T, GOTO K, MASAKI T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86, 2863-2867, 1989.
5. DONCKIER JE, HANET C, BERBINSCHI A, GALANNTI L, ROBERT A, VAN MECHELIN H: Cardiovascular and endocrine effects of ET-1 at pathophysiological and pharmacological plasma concentration in conscious dogs. Circulation 84, 2476-2484, 1991.
6. 2+ transients and contractility in rabbit ventricular myocardium. Life Sci 62, 1485-1489, 1998.
7. TUKAWA Y: Endothelin in vascular and endocrine systems: biological activities and its mechanisms of action. Endor J 40, 489-506, 1993.
8. GIAID A, GIBSON SJ, HERRERO MT, GENTELMAON S, LEGON S, YANAGISAWA M, MASAKI T, IBRAHIM BN, ROBERTS GW, ROSSI ML, POLAK JM: Topographical localization of endothelin mRNA and peptide immunoreactivity in neurons of the human brain. Histochemistry 95, 303-314, 1991.
9. YANAGISAWA M, MASAKI T: Endothelin, a novel endothelium-derived peptide. Biochem Pharmacol 38, 1877-1886, 1989.
10. HAYNES WG, FERRO CHE, WEBB DJ: Physiological role of endothelin in maintenance of vascular tone in human. J Cardiovasc Pharmacol 26, 183-185, 1995.
11. GELLAI M, FLETCHER T, PULLEN M, NAMBI P: Evidence for the existance of endothelin-B receptor subtypes and their physiological roles in the rat. Am J Physiol (Regulatory Integrative Comp. Physiol 40), 27, R254-R261, 1996.
12. JOSKO J, GWOZDZ B, HENDRYK S, JEDRZEJEWSKA-SZYPULKA H, SLOWINSKI J, JOCHEM J: Expression of vascular endothelial growth factor (VEGF) in rat brain after subarachnoid haemorrhage and endothelin receptor blockade with BQ-123. Folia Neuropathol 39, 243-251, 2001.
13. LERMAN A, HOLMES DR, MALCOLM R, BELL MBB, GARRATT KN, NISHIMURA RA, BURNETT JC: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 92, 2426-2431, 1995.
14. HALCOX JP, NOUR KR, ZALOS G, QUYYUMI AA: Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) recptor blockade. Circ Res 89:969-976, 2001.
15. YORICANE R, SHIGA H, MIYAKE S, KOIKE H: Evidence for direct arrhytmogenic action of endothelin. Biochem Biophys Res Commun 173, 457-462, 1990.
16. KRAMER BK, ITTNER KP, BEYER ME, HOFFMEISTER HM, RIEGGER GAJ: Circulatory and myocardial effects of endothelin. J Mol Med 75, 886-890, 1997.
17. GROSSMAN JD, MORGAN JP: Cardiovascular effects of endothelin. News Physiol Sci 12, 113-117, 1997.
18. CAIN AE, TANNER DM, KHALL RA: Endothelin-1-induced enhancement of coronary smooth muscle contraction via MAPK-dependent and MAPK-independent [Ca(2+)](i)sensitization pathways. Hypertension 39 (2Pt2):543-549, 2002.
19. MORTENSEN LH, FINK GD: Salt-dependency of endothelin-induced chronic hypertension in conscious rat. Hypertension 19, 549-554, 1992.
20. YANG Z, VON SEGESSER L, BAUER E, SCHULTZ P, TURINA M, LÜSCHER TF: Different mobilization of calcium in endothelin-1 induced contractions in human arteries and veins: Effect of calcium antagonists. J Cardiovasc Pharmacol 16: 654-660, 1990.
21. ZOLK O, QUATTEK J, SEELAND U, EL-ARMOUCHE A, ESCHENHAGEN T, BOHM M: Activation of the cardiac endothelin system in left ventricular hypertrophy before onset of heart failure in TG(mREN2)27 rats. Cardiovasc Res 53, 363-371, 2002.
22. FICAI S, HERIZI A, MIMRAN A, JOVER B: Endothelin blockade in angiotensin ii hypertension: prevention and treatment studies in the rat. Clin Exp Pharmacol Physiol 28, 1100-1103, 2001.
23. BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHAFERS HJ: Selective upregulation of endothelin B receptor gene expression in serve pulmonary hypertension. Circulation 105, 1034-1036, 2002.
24. DING SS, QIU C, HESS P, XI JF, CLOZEL JP, CLOZEL M: Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc Res 53, 963-970, 2002.
25. RUBIN LJ, BADESCH DB, BARST RJ, GALIE N, BLACK CM, KEOGH A, PULIDO T, FROST A, Roux S, LECONTE I, LANDZBERG M, SIMONNEAU G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346, 896-903, 2002.
26. LOVE M: Endothelin in heart failure: a promising therapeutic target?. Heart 77, 93-100, 1997.
27. KINLAY S, BEHRENDT D, WAINSTEIN M, BELTRAME J, FANG JC, CREAGER MA, SELWYN AP, GANZ P: Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation 104, 1114-1118, 2001.
28. CROCKETT TR, SCOTT GA, MCGOWAN NW, KANE KA, WAINWROGHT CL: Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur J Pharmacol 432, 71-77, 2001.
29. RASCHAK M, UNGER L, RIECHERS H, KLINGE D: Receptor selectivity of endothelin antagonists and prevention of vasoconstrictor and endothelin-induced sudden death. J Cardiovasc Pharmacol 26 (suppl 3), 397-399, 1995.
30. KOJIMA M, KUSUMOTO K, FUJIWARA S, WATANABE T, FUJINO M: Role of endogenous endothelin in the extension of myocardial infarct size studied with the endothelin receptor antagonist TAK-044. J Cardiovac Pharmacol 26 (suppl. 30), 365-368, 1996.
31. BARTON M, KIOWSKI W: The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Curr Hypertens Rep 3, 322-330, 2001.
32. ISHIKAWA T, YANAGISAWA M, KIMURA S, GOTO K, MASAKI T: Positive inotropic action of novel vasoconstrictor endothelin on guinea pig atria. Am J Physiol 255, H970-H973, 1988.
33. + exchanger. Circ Res 68, 269-279, 1991.
34. A receptors Fr 139317. J Pharmacol Exp Therap 277, 61-70, 1996.
35. HILAL-DANDAN R, MERCK DT, LUJAL JP, BRUNTON LL: Coupling of the type A endothelin receptor to multiple responses in adult rat cardiac myocytes. Mol Pharmacol 45, 1183-1190, 1994
36. MAC CARTHY PA, GROCOTT-MASON R, PRENDERGAST BD, SHAH AM: Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 101, 142-147, 2000.
37. WOO SH, LEE CO: Effects of endothelin-1 on Ca2+ signaling in guinea pig ventricular myocytes: role of protein kinase C. J Moll Cell Cardiol 31, 631-643, 1999.
38. ZHU Y, YANG H-T, ENDOH M: Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol 273 (Heart Circ Physiol 42):, H119-H127, 1997.
39. GELLER L, MERKELY B, SZOKODI I, SZABO T, VECSEY T, JUHASZ-NAGY A, TOTH M, HORKAY F: Electophysiological effects of intrapericardial infusion of endothelin-1. Pace 21, 151-156, 1998.
40. SHRIF I, CROCKETT TR, KANE KA, WAINWRIGHT CL: The effects of endothein-1 on ischaemia-induced ventricular arrhythmias in rat isolated hearts. Eur J Pharmacol 427, 235-242, 2001.
41. LAGHMANI K, PREISIG PA, ALPERN RJ: The role of endothelin in proximal tubule proton secretion and the adaptation to a chronic metabolic acidosis. J Nephrol 15, suppl. 5, 75-87, 2002.
42. LIN H, MARIEM S, SMITH MJ, JR, YOUNG DB: Effect of endothelin-1 on glomerular hydraulicpressure and renin release in dogs. Hypertension 21, 845-851, 1993.
43. TIAN X, TANG G, CHEN Y: The effects of endothelin-1 selective endothelin receptor-type A antagonist on human renal interstitial fibroblasts in vitro. Zhoghua Yi Xue Za Zhi 82, 5-9, 2002.
44. WENECEK M, OLDNER A, SUNDIN P, ALVING K, WEITZBERG E, RUDEHILL A: Effects on haemodynamics by selective endothelin ET(B) receptor and combined endothelin ET(A)/ET(B) receptor antagonism during endotoxin shock. Eur J Pharmacol 386: 235-245, 1999.
45. LETIZIA C, DE BIASE L, CALIUMI C, VERRELLI C, SEMERARO R, SUBIOLI S, CERCI S, D'ERASMO E: Endothelin-1 circulating levels increase in patients with orthotopic heart transplantation and in chronic therapy with cyclosporine. Minerva Cardioangiol 49, 15-22, 2001.
46. IVY DD, YANAGISAWA M, GARIEPY CE, GEBB SA, COLVIN KL, MC MURTRY IF: Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 282, L703-712, 2002.
47. MOSTAFA MG, MIMA T, TANIGUCHI T, MORI K: Doxorubicin, an RNA synthesis inhibitor, prevents vasoconstriction and inhibits aberrant expression of endothelin-1 in the cerebral vasospam model of the rat. Neurosci Lett 283, 197-200, 2000.
48. MIGDALIS IN, KALOGEROPOULOU K, KARMANIOLAS KD, VARVARIGOS N, MORTZOS G, CORDOPATIS P: Plasma levels of endothelin and early carotid atherosclerosis in diabetic patients. Res Commun Mol Pathol Pharmacol 108, 15-25, 2000.
49. IHLING C, SZOMBATHY T, BOHRMANN B, BROCKHAUS M, SCHAEFER HE, LOEFFLER BM: Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 104, 864-869, 2001.
50. PALMA BD, GABRIEL A, JR, BIGNOTTO M, TUFIK S: Paradoxal sleep deprivation increases plasma endothelin levels. Braz J Med Biol Res 35, 75-79, 2002.